The report serves as a progress update for the Infectious Diseases Society of America’s 10 x ’20 initiative, which aims for 10 new systemic antibacterial agents to earn FDA approval by 2020. IDSA released its last antibiotic pipeline status report in 2013.
Four takeaways from the report:
1. The amount of antibiotics approved annually in the U.S. has increased since 2013, likely due to more financial incentives and increased regulatory flexibility, researchers noted.
2. However, most new approvals involved modification of an existing antibiotic class, rather than the creation of a new antibiotic class.
3. Researchers also noted large drug companies are abandoning antibiotic research, while smaller companies responsible for most new antibiotic development are struggling to stay in business.
4. The report calls for more incentives to fuel antibiotic development, improved stewardship to maintain the effectiveness of existing antibiotics, and increased collaboration among regulatory, federal and industry stakeholders.
More articles on clinical leadership & infection control:
New York hospital mishandled complaints about physician, CMS finds
Texas hospitals harness ‘teletrauma’ technology to care for rural patients
Atlanta surgeons perform novel reconstruction procedure to help toddler walk
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
